<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678416</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14504055</org_study_id>
    <nct_id>NCT02678416</nct_id>
  </id_info>
  <brief_title>Reduction in Pain Intensity Following IV or Oral Pain-relieving Products</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Two-Part, Cross-over Study in Healthy Adult Male Subjects to Compare the Reduction in Pain Intensity After Single-Dose Administration of Intravenous or Oral Acetaminophen and Intravenous Morphine by Using UVB Burn and Intradermal Capsaicin Experimental Pain Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate two experimental pain models to see if they would be
      useful for comparing different products for reduction in pain intensity.

      The models evaluated were the ultraviolet-B (UVB) burn and intradermal capsaicin experimental
      pain models. Medications compared were a single dose each, of intravenous (IV) acetaminophen,
      oral acetaminophen, placebo, and IV morphine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2015</start_date>
  <completion_date type="Actual">June 13, 2016</completion_date>
  <primary_completion_date type="Actual">June 13, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model</measure>
    <time_frame>within 6 hours</time_frame>
    <description>The UVB burn pain model is a validated screening tool for pain killers in clinical drug development. A temperature of 50 degrees centigrade (°C) is used to burn the participant for 5 seconds. Then the participant rates his pain on a scale from 0 (no pain) to 10 (most intense pain). That score is recorded as baseline. Then the participant rates his pain again six hours after taking the assigned medication. The average at baseline is subtracted from the average at hour 6. Because this is a measure of reduction in pain intensity, a higher score is better (it means there is more pain relief).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area</measure>
    <time_frame>within 6 hours</time_frame>
    <description>Participants rated their pain intensity on a scale of 0 (no pain) to 10 (most intense pain). The observed mean and standard deviation are disclosed through Hour 6</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive IV acetaminophen as one of 4 interventions in random sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive oral acetaminophen as one of 4 interventions in random sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive placebo as one of 4 interventions in random sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive morphine as one of 4 interventions in random sequence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen (Treatment A)</intervention_name>
    <description>Acetaminophen administered by intravenous (IV) infusion</description>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <other_name>OFIRMEV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Acetaminophen (Treatment B)</intervention_name>
    <description>Acetaminophen administered by oral tablets</description>
    <arm_group_label>Oral Acetaminophen</arm_group_label>
    <other_name>Acetaminophen tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Treatment C)</intervention_name>
    <description>Placebo administered by IV infusion or oral tablets</description>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Oral Acetaminophen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>IV Placebo</other_name>
    <other_name>Placebo tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Morphine (Treatment D)</intervention_name>
    <description>Morphine administered by IV infusion</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>IV Morphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Must have a health status of &quot;healthy&quot; assessed by the investigator and defined as no
             clinically significant deviation from normal medical history, physical examination,
             vital signs, and clinical laboratory determinations.

          2. Must be male, Caucasian, between 18 and 55 years of age (inclusive) at the time of the
             screening.

          3. Must have a body mass index (BMI) ≥ 19.0 and ≤ 30.0 kg/m2 with a minimum weight of 110
             pounds (50 kg) at screening.

        Exclusion Criteria

          1. A positive test result for human immunodeficiency virus (HIV), hepatitis B (surface
             antigen), or hepatitis C virus antibody at Screening.

          2. A history of any drug allergy, hypersensitivity, or intolerance to acetaminophen,
             morphine, or capsaicin or to any of the excipients in the IV or oral formulations
             used.

          3. A positive test result for drugs of abuse, alcohol, or cotinine.

          4. Fitzpatrick Skin Type V or VI (based on a Skin Type score of greater than 30.

          5. A history of conditions which might be specifically contraindicated or require caution
             to be used during the administration of any drug in the study.

          6. Any other medical, psychiatric and/or social reason for exclusion as determined by the
             investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaceuticals Research Associates, Inc. (PRA)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <results_first_submitted>June 28, 2017</results_first_submitted>
  <results_first_submitted_qc>November 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 20, 2019</results_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>comparison</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 79 participants were enrolled in the study. 12 participants in Part 1 and 66 participants in Part 2 were randomized to sequence, and received at least one dose of the study treatment.</recruitment_details>
      <pre_assignment_details>One participant in Part 2 was randomized but discontinued without receiving treatment due to an adverse event.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1</title>
          <description>All participants receive all products in random sequence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67">Part 2 enrolled all new participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated (Safety Population)</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Population</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population, defined as participants enrolled in the study that received any quantity of study drugs. All new participants were enrolled in Part 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1</title>
          <description>All participants who received a drug product in Part 1</description>
        </group>
        <group group_id="B2">
          <title>Part 2</title>
          <description>All participants who received a drug product in Part 2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" lower_limit="19" upper_limit="49"/>
                    <measurement group_id="B2" value="26.5" lower_limit="18" upper_limit="52"/>
                    <measurement group_id="B3" value="26.9" lower_limit="18.2" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race, White</title>
              <category_list>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model</title>
        <description>The UVB burn pain model is a validated screening tool for pain killers in clinical drug development. A temperature of 50 degrees centigrade (°C) is used to burn the participant for 5 seconds. Then the participant rates his pain on a scale from 0 (no pain) to 10 (most intense pain). That score is recorded as baseline. Then the participant rates his pain again six hours after taking the assigned medication. The average at baseline is subtracted from the average at hour 6. Because this is a measure of reduction in pain intensity, a higher score is better (it means there is more pain relief).</description>
        <time_frame>within 6 hours</time_frame>
        <population>Completers, defined as participants who were enrolled in the study, took the entire dose of all study drugs, and provided all pain intensity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>All participants received IV acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Oral Acetaminophen</title>
            <description>All participants received oral acetaminophen</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>All participants received placebo</description>
          </group>
          <group group_id="O4">
            <title>Morphine</title>
            <description>All participants received morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in Pain Intensity at Hour 6 Using the Thermal Suprathreshold Pain in the Ultraviolet-B (UVB) Burn Pain Model</title>
          <description>The UVB burn pain model is a validated screening tool for pain killers in clinical drug development. A temperature of 50 degrees centigrade (°C) is used to burn the participant for 5 seconds. Then the participant rates his pain on a scale from 0 (no pain) to 10 (most intense pain). That score is recorded as baseline. Then the participant rates his pain again six hours after taking the assigned medication. The average at baseline is subtracted from the average at hour 6. Because this is a measure of reduction in pain intensity, a higher score is better (it means there is more pain relief).</description>
          <population>Completers, defined as participants who were enrolled in the study, took the entire dose of all study drugs, and provided all pain intensity assessments.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="1.104"/>
                    <measurement group_id="O2" value="-0.64" spread="1.804"/>
                    <measurement group_id="O3" value="-0.36" spread="1.567"/>
                    <measurement group_id="O4" value="0.36" spread="1.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area</title>
        <description>Participants rated their pain intensity on a scale of 0 (no pain) to 10 (most intense pain). The observed mean and standard deviation are disclosed through Hour 6</description>
        <time_frame>within 6 hours</time_frame>
        <population>Per-Protocol Population, defined as participants who were enrolled in the study, have taken the entire dose of all study drugs, and provided all pain intensity assessments designed for the UVB Burn Pain Model without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: IV Acetaminophen</title>
            <description>All participants received IV acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Oral Acetaminophen</title>
            <description>All participants received oral acetaminophen</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Placebo</title>
            <description>All participants received placebo</description>
          </group>
          <group group_id="O4">
            <title>Part 2: IV Morphine</title>
            <description>All participants received morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Observed Thermal Suprathreshold Pain Intensity in the UVB Burn Area</title>
          <description>Participants rated their pain intensity on a scale of 0 (no pain) to 10 (most intense pain). The observed mean and standard deviation are disclosed through Hour 6</description>
          <population>Per-Protocol Population, defined as participants who were enrolled in the study, have taken the entire dose of all study drugs, and provided all pain intensity assessments designed for the UVB Burn Pain Model without a major protocol deviation.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.30"/>
                    <measurement group_id="O2" value="5.5" spread="1.40"/>
                    <measurement group_id="O3" value="5.5" spread="1.32"/>
                    <measurement group_id="O4" value="5.6" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.39"/>
                    <measurement group_id="O2" value="5.3" spread="1.48"/>
                    <measurement group_id="O3" value="5.5" spread="1.28"/>
                    <measurement group_id="O4" value="4.9" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="1.34"/>
                    <measurement group_id="O2" value="5.1" spread="1.36"/>
                    <measurement group_id="O3" value="5.3" spread="1.28"/>
                    <measurement group_id="O4" value="4.7" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.75 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="1.37"/>
                    <measurement group_id="O2" value="5.1" spread="1.30"/>
                    <measurement group_id="O3" value="5.4" spread="1.26"/>
                    <measurement group_id="O4" value="4.7" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="1.44"/>
                    <measurement group_id="O2" value="4.9" spread="1.23"/>
                    <measurement group_id="O3" value="5.2" spread="1.34"/>
                    <measurement group_id="O4" value="4.6" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="1.13"/>
                    <measurement group_id="O2" value="5.1" spread="1.26"/>
                    <measurement group_id="O3" value="5.6" spread="1.28"/>
                    <measurement group_id="O4" value="5.1" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.30"/>
                    <measurement group_id="O2" value="5.2" spread="1.44"/>
                    <measurement group_id="O3" value="5.5" spread="1.23"/>
                    <measurement group_id="O4" value="5.0" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="1.17"/>
                    <measurement group_id="O2" value="5.4" spread="1.40"/>
                    <measurement group_id="O3" value="5.5" spread="1.30"/>
                    <measurement group_id="O4" value="5.2" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.32"/>
                    <measurement group_id="O2" value="5.5" spread="1.30"/>
                    <measurement group_id="O3" value="5.5" spread="1.34"/>
                    <measurement group_id="O4" value="5.4" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose up to Day 46</time_frame>
      <desc>Safety population included participants enrolled in the study that received any quantity of study medications.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: IV Acetaminophen</title>
          <description>All participants received IV acetaminophen</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Oral Acetaminophen</title>
          <description>All participants received oral acetaminophen</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Placebo</title>
          <description>All participants received placebo</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Morphine</title>
          <description>All participants received morphine</description>
        </group>
        <group group_id="E5">
          <title>Part 2: IV Acetaminophen</title>
          <description>All participants received IV acetaminophen</description>
        </group>
        <group group_id="E6">
          <title>Part 2: Oral Acetaminophen</title>
          <description>All participants received oral acetaminophen</description>
        </group>
        <group group_id="E7">
          <title>Part 2: Placebo</title>
          <description>All participants received placebo</description>
        </group>
        <group group_id="E8">
          <title>Part 2: Morphine</title>
          <description>All participants received morphine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Altered visual depth perception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Head Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Feeling Of Relaxations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Eye Movement Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators will be part of the primary publication. Each investigator may publish on the data from subjects enrolled at their site after the initial publication has been submitted.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>800-556-3314 ext 5</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

